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Adverse reactions to antibiotics in patients with cystic fibrosis (CF) are a growing concern. We report the case of a pediatric patient with CF
with multiple comorbidities and a history of drug reactions, who developed life-threatening piperacillin-induced immune hemolytic anemia. We
review drug-induced hemolytic anemia (DIIHA) in particular, and antibiotic hypersensitivity in CF in general, including the frequency,
pathogenesis, and risk factors. Finally, we discuss the treatment options and propose an algorithm for the management of drug-induced
hypersensitivity reactions in patients with CF.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Patients with cystic fibrosis (CF) are exposed to a broad
array of antibiotics utilized for the control, eradication, and
prophylaxis of pathogenic organisms as well as for their chronic
anti-inflammatory effects. Oral, intravenous, and inhaled
antibiotic courses are often frequent and prolonged, especially
with increasing age and declining pulmonary status. Antibiotic
selection is often challenging due to the emergence of antibiotic
resistant strains of Pseudomonas and Staphylococcus aureus;
these challenges become progressively more complicated when
patients develop an adverse reaction to a preferred antibiotic,
further constraining alternative antibiotic choices. We report a
case of a life-threatening reaction to piperacillin in a patient with
CF, we discuss factors associated with adverse reactions to☆ This case report was presented at the North American Cystic Fibrosis
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previously published.
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doi:10.1016/j.jcf.2010.08.010antibiotics and we present a therapeutic algorithm to aid in the
management of adverse reactions. Our patient's presentation
points out the complexity in arriving at the diagnosis of DIIHA
given that many CF patients have multiple comorbidities, and
highlights the fact that one patient can have multiple types of
immune mediated drug reactions.
2. Case report
A 17-year-old female patient with CF was admitted for a
pulmonary exacerbation and started on intravenous (IV)
tobramycin and piperacillin/tazobactam for the treatment of
multi-drug resistant Pseudomonas aeruginosa. She had been
diagnosed with CF (dF508/G1244E mutations) at 2 months of
age due to failure to thrive. Her CF manifestations included
moderate pulmonary disease, pancreatic insufficiency, and
intermittent distal intestinal obstruction syndrome. She also
had a history of nephrolithiasis and cholelithiasis that were
treated with a ureteral stent placement and cholecystectomy,
respectively.
On the 5th day of hospitalization, the patient developed acute
appendicitis and underwent an appendectomy. The following
day, she suddenly developed pallor, severe hypoxemia and
hypotension, with an acute drop in hematocrit (from 34.3% tod by Elsevier B.V. All rights reserved.
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resuscitation including 3 U of packed red blood cells. An
abdominal ultrasound was negative for gross hemorrhage.
Studies evaluating the etiology of acute anemia indicated a
hemolytic process, including a strongly reactive direct anti-
globulin test (DAT, also known as the Direct Coombs' test), a
decreased haptoglobin level (b10 mg/dl; 30–200 mg/dl), an
elevated reticulocyte count (2.7%; 0.5–1.5%) and LDH
(1520 U/l; 340–670 U/l), and an indirect hyperbilirubinemia
(total bilirubin of 2.9 mg/dl; 0.6–1.4 mg/dl; direct bilirubin of
b0.1 mg/dl). Review of the peripheral blood smear showed
schistocytes with polychromasia, normal platelets and normal
white blood cells. The differential diagnosis for her hemolytic
anemia included drug-induced etiologies assessed by testing the
patient's serum in the presence of piperacillin and tazobactam
separately, using untreated and ficin-treated red blood cells
(RBCs). In the presence of tazobactam, the patient's serum did
not react; however, in the presence of piperacillin, her serum
reacted weakly with untreated RBCs but strongly with ficin-
treated RBCs. Thus, an antibody to piperacillin was detected in
the patient's serum.
The patient was treated with a two week course of steroids as
she continued antibiotic treatment with tobramycin and
aztreonam. Her hematocrit remained stable for the remainder
of her hospitalization and on follow up over the following
8 months.
The patient had previously been treated with piperacillin/
tazobactam without any adverse reactions; however, she had a
history of 2 previous reactions to antibiotics. The first involved
an urticarial rash as a young child while receiving oral
cephalexin. The second occurred during a hospitalization
7 months previous, when she was treated with IV piperacillin/
tazobactam, aztreonam, and meropenem; however, the mer-
openem was discontinued after 5 days based on sputum culture
results. After 12 days of IV treatment, she developed acute
cholecystitis; piperacillin/tazobactam was discontinued and
meropenem was restarted to reduce the risk of piperacillin-
induced thrombocytopenia prior to cholecystectomy. Within
1 day of restarting IV meropenem treatment, she developed an
erythematous rash that improved with its discontinuation.
Intravenous tobramycin was added to her therapy and she
subsequently developed a generalized urticarial rash that was
treated with antihistamines. Following allergy consultation, all
antibiotics were discontinued due to improved clinical course
and adequate length of therapy; skin testing to IV and inhaled
tobramycin was negative.
3. Discussion
3.1. Frequency of adverse reactions
Measuring the rate of adverse drug reactions is complicated
as multiple immunologic mechanisms and organ systems can be
associated with reactions. IgE mediated allergic reactions are
only a small proportion of reported adverse drug reactions [1–
3]. The Boston Collaborative Drug Surveillance Program [4]
looked at the rate of cutaneous reactions to all drugs inhospitalized patients. They report 2.2% of patients developing a
rash after receiving any drug, with amoxicillin, ampicillin, and
co-trimoxazole having the highest rates (5.1, 4.5, and 3.7%,
respectively). A more recent study in the Netherlands found a
1% frequency of rash to all antibiotics; those with a higher
frequency were trimethoprim with sulfonamides (2.1%),
fluoroquinolones (1.6%), and penicillins (1.1%) [5].
It has been noted, however that patients with CF have an
increased incidence of adverse drug reactions than the general
population [1,6]. A recent report of pediatric CF patients in the
United Kingdom showed that 23 of 104 (22%) patients had an
adverse reaction to IV antibiotics, with rash, itching, nausea and
vomiting as the most common symptoms [3]. Another pediatric
CF study looking at all antibiotic exposure, found that 18 of 53
(33%) patients experienced some type of adverse reaction after
receiving an antibiotic, with the IV route being the most allergenic
[7]. Two adult CF patient series, reported reactions in 36% and
62% of patients treated with beta-lactam antibiotics [8,9].
Drug-induced immune hemolytic anemia (DIIHA) is rare,
and thus difficult to measure accurately, but the incidence is
estimated to be around 1 in 1 million [10]. The American Red
Cross Blood Services, Southern California Region, performed
25 tests for piperacillin antibody detection and had 12 positive
results from 1999 to 2008 (10, direct communication with
laboratory staff). Six of the 12 positive tests were from patients
with CF between the ages of 15 and 37 years. A recent report
from the Institute for Transfusion Medicine in Berlin, Germany
reported that 8 patients with piperacillin-induced DIIHA, 5 of
whom had CF [11]. The Blood Center of Wisconsin, Inc.,
reported 5 cases of piperacillin antibodies over a 20 year period
(the underlying diagnosis was not reported) [12].
3.2. Types of reactions and pathogenesis
3.2.1. Non-immune mediated drug reactions
Non-immune mediated adverse drug reactions are most
common and can occur even upon first exposure. These
reactions are further sub-divided into predictable and unpre-
dictable reactions. Predictable reactions include known phar-
macologic side effects, drug toxicity, drug–drug interactions,
and drug overdose. Unpredictable reactions are classified as
pseudoallergic reactions, such as red man syndrome with
vancomycin due to direct mast cell activation; idiosyncratic
reactions, when the reaction cannot be explained by the known
pharmacologic action of the drug; and intolerance, when the
reaction occurs at a lower threshold than is normally expected,
such as tinnitus after a single dose of aspirin [13].
3.2.2. Immune mediated reactions
Immune mediated reactions involve an immunologic
response to a drug in a previously exposed or sensitized patient.
These reactions are commonly referred to as drug hypersensi-
tivity reactions/drug allergy and are frequently IgE mediated
reactions. Immune mediated reactions are classified by the Gell
and Coombs system (see Table 1). Adverse drug reactions such
as erythema multiforme major and other blistering disorders are
also immune mediated, but are not well-classified using this
Table 1
Gell and Coombs classification of hypersensitivity reactions.
Type of reaction Mediators Clinical manifestations Drug example Exposure to reaction time Laboratory tests
I — Immediate IgE Bronchospasm Anaphylaxis from
beta-lactam antibiotic
Minutes to hours Skin testing
Anaphylaxis Antigen-specific IgE
II — Cytotoxic,
antibody-dependent
IgM or IgG
complement
Hemolytic anemia Hemolytic anemia
from penicillin
Variable DAT
Thrombocytopenia IAT
Erythroblastosis fetalis
Goodpasture syndrome
III — Immune
complex
IgG complement Serum sickness Serum sickness from
cefaclor
1–3 weeks ESR
Systemic lupus
erythematosis
CRP
Arthus formation Complement studies
ANA
Tissue biopsy
IV — Delayed type
hypersensitivity,
antibody-independent
T-cells Chronic transplant rejection Contact dermatitis
from topical antihistamine
2–7 days Patch testing
Contact dermatitis Lymphocyte
proliferation assay
DAT: Direct Antiglobulin Test (Coombs' test).
IAT:Indirect Antiglobulin Test.
ESR: Erythrocyte Sedimentation Rate.
CRP: C-Reactive Protein.
ANA: Antinuclear antibody.
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more than one type of reaction, such as a maculopapular rash
(Type IV) and anaphylaxis (Type I).
Immune mediated reactions in cystic fibrosis patients are
caused by the same mechanisms as the general population. At
present, it is not clear whether the CF disease process itself, with
the associated immune hyperactivation, or the frequent, high-
dose, long duration courses of antibiotics, or some combination,
contributes to the increased incidence of adverse drug reactions
in this population. In general, beta-lactam antibiotics are more
likely than other classes of antibiotics to cause an allergic
reaction due to their immunogenic nature [15]. Beta-lactams
inhibit cell-wall synthesis by binding to enzymes that bacteria
use to build cell walls. This mechanism of action makes them
highly susceptible to haptenization, defined as the process of
binding to another protein and eliciting an immune response
when the hapten-carrier is recognized by antibody.
DIIHA is a type II reaction that was initially described in
1952 with the drug apronalide [16]. Since then, the list of drugs
with serologic evidence for causing DIIHA has grown to over
100 [10]. Historically, penicillin was the most common
antibiotic associated with DIIHA, but as its use waned,
cephalosporins have become the more common culprits,
especially cefotetan and ceftriaxone [12,17]. However, among
patients with CF, piperacillin stands out for causing DIIHA. An
explanation has been offered by Bandara et al. [18], where the
altered function of the cystic fibrosis transmembrane conduc-
tance regulator decreases the nitric oxide available for
vasodilation, thereby increasing the risk of red blood cell
sludging in the microcirculation.
3.3. Risk factors
In general, the chemical properties and molecular weight of
the drug and its biologic products may partially predict the typeof hypersensitivity reaction [2]. Larger drugs with more
complex structures [13] and those that tend to undergo
haptenization are more likely to be immunogenic. Piperacillin
had the highest incidence of hypersensitivity reactions in a
pediatric patient population with a 19–38% reaction rate [7,19].
The reaction rate in adults ranged from 24 to 50% [8,9,20,21].
In patients with CF, frequent and repeated use of beta-lactams
increases the cumulative dose and the risk of sensitization to the
antibiotic [15,19]. The route of administration also plays a role,
with IV and intramuscular routes being more immunogenic than
the oral and inhaled routes [7]. A previous history of
hypersensitivity to a chemically-related drug also increases
the risk [2].
Burrows et al. looked at risk factors specifically in patients
with CF that had a hypersensivity reaction to beta-lactams [8].
Factors predicting an increased likelihood of reaction included
reduced lung function (FEV1 predicted), advancing age and
greater cumulative exposure to the antibiotic. Interestingly,
cystic fibrosis transmembrane conductance regulator (CFTR)
gene status, gender, peripheral eosinophil count and total IgE
did not adequately predict those at greater risk for reaction.
3.4. Diagnosis and management
When a patient with CF develops a reaction during a course
of antibiotic treatment, the first step should be to decide whether
the reaction is related to the drug that was administered, and if
associated, determine whether the reaction is an immune or non-
immune mediated reaction. The importance of a complete and
correct medical history cannot be overestimated since erroneous
diagnosis of drug allergy can lead to unnecessary limitation of
antibiotic agents.
For IgE mediated reactions, skin testing may be helpful but is
limited due to the lack of appropriate immunogens for the test.
A negative skin test may indicate insufficient sensitivity of the
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not used. For penicillin, however, the relevant antigenic
determinants are well characterized and skin testing is highly
accurate. Empedrad et al. have published nonirritating con-
centrations for skin testing with commonly used antibiotics to
facilitate testing in the office setting [22]. Penicillin immuno-
assay testing is available, but is not sensitive or specific.
Since the immune mechanisms involved in non-IgE
mediated reactions is heterogeneous and are not yet completely
understood, there is only a limited number of available tests.
Serological tests include the DAT for red cell-bound antibodies,
complement levels, and serum tryptase, which is a mast-cell-
specific neutral protease that rises after anaphylactic reactions.
Importantly, since these tests need to be performed during or
soon after the reaction occurs, they require a high index of
suspicion for a drug reaction. In Europe, drug-specific T-cell
detection with in vitro lymphocyte transformation tests may be
applicable.
DIIHA presents with non-specific signs and symptoms that
are related to a decrease in hemoglobin. Our patient developed
symptoms at 6 days after the initiation of therapy with
piperacillin although other reports vary from 7 to 13 days (see
Table 2). Depending on the drug, a specialized laboratory can
perform drug-specific testing using the conventional drug-
coated RBC and/or the immune complex method of detection.
However, it is important to note that while testing is specific for
a diagnosis of DIIHA, it is not sensitive. For piperacillin, it has
been shown that testing in the presence of drug is more accurate
than testing with drug-coated RBCs only [12,19].
We suggest a therapeutic algorithm for adverse drug
reactions in patients with CF modified from published
references [1] and [2] (see Fig. 1).
Generally, any antibiotic causing a severe immune mediated
adverse reaction should be avoided in that patient. Since this
limits the anti-pseudomonals available for future bronchopul-
monary exacerbations, careful documentation and appropriate
diagnostic testing is strongly recommended in patients
demonstrating adverse reactions. If an immune mediated
reaction is suspected, the previous reaction was not life-Table 2
Previously reported cases of piperacillin-induced DIIHA in patients with CF.
Author/Year Age/Gender Time to on
of DIIHA
1999: Thicket, et al. [23] 34 female 13 days
2002: Arndt, et al. [24] 29 male 11 days
2002: Arndt, et al. [24] 37 male 11 days
2006: Seder, et al. [25] 33 female 7 days
2009: Mayer, et al. [11] 42 female NR
2009: Mayer, et al. [11] 37 female NR
2009: Mayer, et al. [11] 18 female NR
2009: Mayer, et al. [11] 19 female NR
2009: Mayer, et al. [11] 23 female NR
2010: Bandara, et al. [18] 33 female 7 days
2010: Chavez, et al. 17 female 6 days
NR: Not Reported.threatening and the antibiotic is going to be administered again,
an allergist can help with choosing the next step in management.
For IgE mediated reactions, desensitization done by trained
personnel can be utilized prior to each course of the offending
antibiotic. A protocol for rapid desensitization in patients with
cystic fibrosis has been published recently [26]. Notably,
desensitization appears more likely to fail in patients with CF,
presumably due to overlap in etiology of hypersensitivity
reactions. For patients with non-IgE mediated reactions that are
not severe, a graded challenge, also known as provocation
testing, can be done. In this case, initial starting doses are larger
than in desensitization and the interval between doses is more
variable.
The question can be raised as to whether patients with CF
should be monitored for anemia with hemoglobin checks on
initiation of long-term parenteral therapy with a beta-lactam. At
our institution, patients with CF undergoing more than 2 weeks of
IV therapy with beta-lactam have weekly complete blood counts
performed starting at the first week to monitor for signs of bone
marrow suppression [27], but not for DIIHA since this a rare
complication and has a more variable time of onset. To our
knowledge, there is no specific guideline for monitoring for
adverse hematologic reaction for patients with CF on long-term IV
beta-lactams. Thus, we suggest that there should be a high index
of suspicion in patients who have received a large cumulative dose
of beta-lactam antibiotics and those with a previous history of any
reaction to a beta-lactam, with consideration of monitoring with
scheduled complete blood counts.
4. Conclusion
The increasing frequency of multiple drug resistant organ-
isms coupled with the heightened risk of adverse drug reactions
to preferred antibiotics in CF patients presents multiple
challenges to clinicians caring for patients with CF. Our case
highlights the complex nature of adverse drug reactions,
including the varied immunologic and non-immunologic
mechanisms underlying these reactions. The key element for
preventing adverse drug reactions is a high index of suspicionset Lowest hemoglobin
or HCT
Outcome
5.5 g/dl Full recovery
3.9 g/dl Full recovery
10% Death
4.8 g/dl Residual joint pain
4 g/dl Acute renal failure,
full recovery
4.8 g/dl Full recovery
4.4 g/dl Full recovery
5 g/dl Full recovery
1.6 g/dl Hypovolemic shock,
full recovery
4.3 g/dl Persistent joint pain
10.5% Full recovery
Fig. 1. Evaluation and management of drug hypersensitivity reaction (adapted from references [1] and [2]). DRESS: Drug Rash with Eosinophilia and Systemic
Symptoms. CH50: Total complement activity. C: Complement. ESR: Erythrocyte Sedimentation Rate. CRP: C-Reactive Protein. ANA: Antinuclear Antibody.
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include previous history of a reaction, history of receiving a
high cumulative dose, advancing age and poor pulmonary
function. Further, we emphasize that not all immunologic
reactions are IgE mediated reactions, and adverse reactions such
as DIIHA should be a consideration in the diagnosis. We
present a diagnosis and treatment algorithm that emphasizes the
importance of appropriate classification of reactions. It also
emphasizes the importance of appropriate documentation and
communication between clinicians to prevent future adverse
reactions. Since almost 50% of patients with CF reach
adulthood and are subjected to prolonged and repeated exposure
to antibiotics, we feel it is vital for CF centers to develop a
proper documentation system for drug hypersensitivity reac-
tions to avoid future life-threatening events. Prospective multi-
center studies are critical to determine the true prevalence and
mechanisms of these adverse drug reactions in an effort to
improve the care and quality of life of patients with CF.
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